Company Update (NYSE:MRK): Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma

[PR Newswire] – THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy . . . → Read More: Company Update (NYSE:MRK): Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma Similar Articles: Company Update: Merck & Co Inc (NYSE:MRK) – Merck’s Pembrolizumab Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 Market Update: Merck & Co Inc (NYSE:MRK) – U.S. FDA expands approval of Merck’s Keytruda to lung cancer Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present New Data at the European Cancer Congress 2015 Reinforcing the Company’s Patient-Centric Focus